263 related articles for article (PubMed ID: 35432377)
1. Networks of CD8
Fukuda K
Front Immunol; 2022; 13():866703. PubMed ID: 35432377
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.
Byrne KT; Côté AL; Zhang P; Steinberg SM; Guo Y; Allie R; Zhang W; Ernstoff MS; Usherwood EJ; Turk MJ
J Clin Invest; 2011 May; 121(5):1797-809. PubMed ID: 21540555
[TBL] [Abstract][Full Text] [Related]
3. Type I interferon signaling limits viral vector priming of CD8
Riding RL; Richmond JM; Fukuda K; Harris JE
Pigment Cell Melanoma Res; 2021 Jul; 34(4):683-695. PubMed ID: 33040466
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PD-1/PD-L1 Axis in Human Vitiligo.
Willemsen M; Melief CJM; Bekkenk MW; Luiten RM
Front Immunol; 2020; 11():579022. PubMed ID: 33240267
[TBL] [Abstract][Full Text] [Related]
5. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
Byrne KT; Zhang P; Steinberg SM; Turk MJ
J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
[TBL] [Abstract][Full Text] [Related]
7. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
8. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
Carbone ML; Capone A; Guercio M; Reddel S; Silvestris DA; Lulli D; Ramondino C; Peluso D; Quintarelli C; Volpe E; Failla CM
Front Immunol; 2023; 14():1197630. PubMed ID: 37680638
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ-induced PD-L1 expression on human melanocytes is impaired in vitiligo.
Willemsen M; Krebbers G; Tjin EPM; Willemsen KJ; Louis A; Konijn VAL; Narayan VS; Post NF; Bakker WJ; Melief CJM; Bekkenk MW; Luiten RM
Exp Dermatol; 2022 Apr; 31(4):556-566. PubMed ID: 34758170
[TBL] [Abstract][Full Text] [Related]
10. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
11. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
[TBL] [Abstract][Full Text] [Related]
12. MIF inhibition alleviates vitiligo progression by suppressing CD8
Chen J; Guo W; Du P; Cui T; Yang Y; Wang Y; Kang P; Zhang Z; Wang Q; Ye Z; Liu L; Jian Z; Gao T; Bian H; Li S; Li C
J Pathol; 2023 May; 260(1):84-96. PubMed ID: 36852981
[TBL] [Abstract][Full Text] [Related]
13. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.
Wańkowicz-Kalińska A; van den Wijngaard RM; Tigges BJ; Westerhof W; Ogg GS; Cerundolo V; Storkus WJ; Das PK
Lab Invest; 2003 May; 83(5):683-95. PubMed ID: 12746478
[TBL] [Abstract][Full Text] [Related]
14. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo.
Lili Y; Yi W; Ji Y; Yue S; Weimin S; Ming L
PLoS One; 2012; 7(5):e37513. PubMed ID: 22649532
[TBL] [Abstract][Full Text] [Related]
15. Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection.
Xie B; Zhu Y; Shen Y; Xu W; Song X
Expert Opin Ther Targets; 2023 Mar; 27(3):189-206. PubMed ID: 36947026
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.
Wu J; Zhou M; Wan Y; Xu A
Mol Med Rep; 2013 Jan; 7(1):237-41. PubMed ID: 23042234
[TBL] [Abstract][Full Text] [Related]
17. New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT; Turk MJ
Oncotarget; 2011 Sep; 2(9):684-94. PubMed ID: 21911918
[TBL] [Abstract][Full Text] [Related]
18. Multimodal analyses of vitiligo skin identify tissue characteristics of stable disease.
Shiu J; Zhang L; Lentsch G; Flesher JL; Jin S; Polleys C; Jo SJ; Mizzoni C; Mobasher P; Kwan J; Rius-Diaz F; Tromberg BJ; Georgakoudi I; Nie Q; Balu M; Ganesan AK
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35653192
[TBL] [Abstract][Full Text] [Related]
19. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed perforin contributes to the melanocyte destruction via epigenetic regulation in patients with vitiligo.
Deng Q; Zou P; Du P; Shi Y; Pi Z; Xiao Y; Kanekura T; Zhang H; Zhan Y; Qiu X; Ding Y; Zeng Z; Xiao R
Int Immunopharmacol; 2023 Jan; 114():109574. PubMed ID: 36538850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
